American Society of Clinical Oncology

SHERPA: White

People

  1. Scher
    Scher
  2. Morris
    Morris
  3. Carrasquillo
    Carrasquillo
  4. Danila
    Danila
  5. Pandit-Taskar
    Pandit-Taskar
  6. Fleisher
    Fleisher
  7. Lewis
    Lewis
  8. Martinez
    Martinez
  9. O'Donoghue
    O'Donoghue
  10. Rathkopf
    Rathkopf

Groups

  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
  4. Molecular Imaging and Therapy Service (7)
  5. Radiology, Department of (7)
  6. Epidemiology and Biostatistics (5)
  7. GSK Faculty (5)
  8. Molecular Pharmacology and Chemistry Program Faculty (5)
  9. Sloan Kettering Institute Faculty (5)
  10. Biostatistics Service (4)
Search Within
  1. "Howard Scher"
  2. "2015"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (2)
Groups
  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
  4. Molecular Imaging and Therapy Service (7)
  5. Radiology, Department of (7)
  6. Epidemiology and Biostatistics (5)

More Groups

People
  1. Howard Scher (20)
  2. Michael Morris (10)
  3. Dana Rathkopf (6)
  4. Daniel Danila (6)
  5. Jorge Carrasquillo (6)
  6. Neeta Pandit-Taskar (5)

More People

Years
  1. 2015 (20)
Publications
  1. Journal of Clinical Oncology (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Scher, H. I.; Morris, M. J.; Stadler, W. M.; Higano, C. S.; Halabi, S.; Smith, M. R.; Basch, E. M.; Fizazi, K.; Ryan, C. J.; Antonarakis, E. S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Skeletal morbidities in the prostate cancer (PC) patient
    Meeting Abstract

    Ruppert, L. M.; Scher, H. I.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy
    Meeting Abstract

    Morris, M. J.; Hilden, P.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Dayan, E. S.; Filipenko, J.; Acosta, I.; Heller, G.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial
    Meeting Abstract

    Morris, M. J.; Higano, C. S.; Scher, H. I.; Sweeney, C.; Antonarakis, E. S.; Shevrin, D. H.; Ryan, C. J.; Loriot, Y.; Fizazi, K.; Pandit-Taskar, N.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials
    Meeting Abstract

    Lorente, D.; Olmos, D.; Mateo, J.; Bianchini, D.; Seed, G.; Flohr, P.; Crespo, M.; Figueiredo, I.; Miranda, S.; Baeten, K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC)
    Meeting Abstract

    Landers, M.; Greene, S.; Schreiber, N. A.; Rodriguez, A.; Bambury, R. M.; Danila, D. C.; Rathkopf, D. E.; Fleisher, M.; Louw, J.; Jendrisak, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study)
    Meeting Abstract

    Fleisher, M.; Danila, D. C.; Fizazi, K.; Hirmand, M.; Selby, B.; Phung, D.; de Bono, J. S.; Scher, H. I.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591
    Meeting Abstract

    Feldman, J. L.; Morris, M. J.; Martinez, D. F.; Tagawa, S. T.; Nanus, D. M.; Solomon, S. B.; Carrasquillo, J. A.; Reuter, V. E.; Lewis, J. S.; O'Donoghue, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Fleisher, M.; Carrasquillo, J. A.; Gilbert, H.; Morris, M. J.; Bellomo, L. P.; Hendrikx, P. J.; Szafer-Glusman, E.; Herkal, A.; Patel, C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay
    Meeting Abstract

    Abida, W.; Curtis, K. R.; Taylor, B. S.; Arcila, M. E.; Brennan, R.; Danila, D. C.; Rathkopf, D. E.; Morris, M. J.; Slovin, S. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save